ArticleFrontiers in pharmacology2024

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.

Takeru Kashiwada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.